The Zhitong Finance App learned that on Wednesday, US diet drug concept stocks strengthened. As of press release, Shuodi Biotech (GPCR.US) had risen more than 5%, Novo Nordisk (NVO.US) had risen more than 3.5%, Roche (RHHBY.US) had risen more than 3%, and Lily.US (LY.US) had risen slightly. According to the news, Schudi Biotech previously announced that its daily oral administration of the small molecule GLP-1 receptor agonist Aleniglipron had positive top-line results in the Access clinical project.

The Zhitong Finance App learned that on Wednesday, US diet drug concept stocks strengthened. As of press release, Shuodi Biotech (GPCR.US) had risen more than 5%, Novo Nordisk (NVO.US) had risen more than 3.5%, Roche (RHHBY.US) had risen more than 3%, and Lily.US (LY.US) had risen slightly. According to the news, Schudi Biotech previously announced that its daily oral administration of the small molecule GLP-1 receptor agonist Aleniglipron had positive top-line results in the Access clinical project.